Literature DB >> 17952424

Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients.

Macarena C Cáceres1, Eva María Peñas-Lledó, Alfredo de la Rubia, Adrián Llerena.   

Abstract

AIM: To analyze the changes in the prescribing pattern of antipsychotic drugs in primary care in Extremadura (Spain) from 1990 to 2005, and the potential association with schizophrenia hospitalization rate.
METHODS: Data from 1990-2005 about the prescribing of antipsychotic drugs was drawn from all community pharmacy sales figures reimbursed by the Health System of Extremadura. Drug consumption figures were expressed as the number of defined daily doses per 1,000 inhabitants and per day of treatment (DDD/1,000/day). The total number of annual hospital discharges with the diagnosis of schizophrenia according to DSM-IV criteria from all hospitals in Extremadura from 1 January 1995 to 31 December 2000 was also determined.
RESULTS: The use of second-generation antipsychotic drugs (SGAs) increased from 0% in 1990-1993 to 78% in 2005. Olanzapine was the most used SGA from 1999-2005. During 1995-2000 the sales of SGAs increased to 50% from 10%. In the same period, the hospitalization rate in schizophrenia patients fell by an average of 12%, which was significantly associated with SGA use (R = -0.88; P = 0.02). DISCUSSION: The increase in SGAs paralleled the decreased rate of hospitalization in schizophrenia patients. However, the influence of other factors such as SGA use for disorders other than schizophrenia can not be ruled out. Moreover changes in the health-care system, such as the increase in primary mental health care and social rehabilitation programs, may also have a relevant influence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952424     DOI: 10.1007/s00228-007-0386-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

Review 1.  Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

Authors:  Stefan Leucht; Thomas R E Barnes; Werner Kissling; Rolf R Engel; Christoph Correll; John M Kane
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

2.  Prescribing and taking medicines.

Authors:  Giselle Jones
Journal:  BMJ       Date:  2003-10-11

3.  Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.

Authors:  Josep Maria Haro; Diego Novick; David Suarez; Jordi Alonso; Jean Pierre Lépine; Mark Ratcliffe
Journal:  J Clin Psychopharmacol       Date:  2006-12       Impact factor: 3.153

4.  [Consumption and cost of antipsychotic drugs].

Authors:  J Pérez; N Marín; A Vallano; X Castells; D Capellà
Journal:  Actas Esp Psiquiatr       Date:  2005 Mar-Apr       Impact factor: 1.196

5.  U.S. national trends in the use of antipsychotics during office visits, 1998-2002.

Authors:  Rajender R Aparasu; Vinod Bhatara; Sanjay Gupta
Journal:  Ann Clin Psychiatry       Date:  2005 Jul-Sep       Impact factor: 1.567

Review 6.  Cost-effectiveness of atypical antipsychotic medications versus conventional medication.

Authors:  Patricia Hanrahan; Daniel J Luchins; Robert Fabian; George Tolley
Journal:  Expert Opin Pharmacother       Date:  2006-09       Impact factor: 3.889

7.  Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002.

Authors:  Gianluca Trifirò; Edoardo Spina; Ovidio Brignoli; Emiliano Sessa; Achille P Caputi; Giampiero Mazzaglia
Journal:  Eur J Clin Pharmacol       Date:  2005-01-22       Impact factor: 2.953

8.  Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002.

Authors:  Mersia Mirandola; Margherita Andretta; Letizia Corbari; Adriano Sorio; Michela Nosè; Corrado Barbui
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-06       Impact factor: 2.890

9.  Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications.

Authors:  F Gianfrancesco; R H Wang; J Pesa; K Rajagopalan
Journal:  Int J Clin Pract       Date:  2006-11       Impact factor: 2.503

10.  Use of antipsychotic agents in Spain through 1985-2000.

Authors:  Blanca Santamaría; Magdalena Pérez; Dolores Montero; Mariano Madurga; Francisco J de Abajo
Journal:  Eur Psychiatry       Date:  2002-12       Impact factor: 5.361

View more
  5 in total

1.  Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users.

Authors:  François Montastruc; Anne Bénard-Laribière; Pernelle Noize; Elodie Pambrun; Fabienne Diaz-Bazin; Marie Tournier; Bernard Bégaud; Antoine Pariente
Journal:  Eur J Clin Pharmacol       Date:  2018-01-06       Impact factor: 2.953

2.  Diffusion of antipsychotics in the US And French markets, 1998-2008.

Authors:  Adeline Gallini; Julie M Donohue; Haiden A Huskamp
Journal:  Psychiatr Serv       Date:  2013-07-01       Impact factor: 3.084

3.  Prescribing pattern of antipsychotic drugs during the years 1996-2010: a population-based database study in Europe with a focus on torsadogenic drugs.

Authors:  Alessandro Oteri; Giampiero Mazzaglia; Serena Pecchioli; Mariam Molokhia; Sinna Pilgaard Ulrichsen; Lars Pedersen; Elisabetta Poluzzi; Fabrizio De Ponti; Edeltraut Garbe; Tania Schink; Ron Herings; Irene D Bezemer; Miriam C J M Sturkenboom; Gianluca Trifirò
Journal:  Br J Clin Pharmacol       Date:  2016-05-18       Impact factor: 4.335

4.  Changing trends in hospitalization rates associated with psychosis: Spain, 1980-2009.

Authors:  Alvaro Medel-Herrero; J M Amate; Z Saz-Parkinson; M Gómez-Beneyto
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-09-28       Impact factor: 4.328

5.  Development of Parkinsonism following exposure to aripiprazole: two case reports.

Authors:  Lannah L Lua; Lin Zhang
Journal:  J Med Case Rep       Date:  2009-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.